Lilly says Phase 3b ADtouch trial shows EBGLYSS beats placebo in hand and foot atopic dermatitis
Company says the study met key goals, with faster skin clearing and improved itch, pain and patient satisfaction versus placebo.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.